» Articles » PMID: 16095645

Bioluminescence Imaging of Vaccinia Virus: Effects of Interferon on Viral Replication and Spread

Overview
Journal Virology
Specialty Microbiology
Date 2005 Aug 13
PMID 16095645
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Whole animal imaging allows viral replication and localization to be monitored in intact animals, which provides significant advantages for determining viral and host factors that determine pathogenesis. To investigate effects of interferons on spatial and temporal progression of vaccinia infection, we generated recombinant viruses that express firefly luciferase or a monomeric orange fluorescent protein. These viruses allow vaccinia infection to be monitored with bioluminescence or fluorescence imaging, respectively. The recombinant viruses were not attenuated in vitro or in vivo relative to a control WR virus. In cell culture, reporters could be detected readily by 4 h post-infection, showing that these viruses can be used as early markers of infection. The magnitude of firefly luciferase activity measured with bioluminescence imaging in vitro and in vivo correlated directly with increasing titers of vaccinia virus, validating imaging data as a marker of viral infection. Replication of vaccinia was significantly greater in mice lacking receptors for type I interferons (IFN I R-/-) compared with wild-type mice, although both genotypes of mice developed focal infections in lungs and brain after intranasal inoculation. IFN I R-/- mice had greater dissemination of virus to liver and spleen than wild-type animals even when mortality occurred at the same time point after infection. Protective effects of type I interferons were mediated primarily through parenchymal cells rather than hematopoietic cells as analyzed by bone marrow transplant experiments. Collectively, our data define a new function for type I interferon signaling in systemic dissemination of vaccinia and validate these reporter viruses for studies of pathogenesis.

Citing Articles

Mpox mRNA-1769 vaccine inhibits orthopoxvirus replication at intranasal, intrarectal, and cutaneous sites of inoculation.

Cotter C, Ignacio M, Americo J, Earl P, Mucker E, Frey T NPJ Vaccines. 2024; 9(1):256.

PMID: 39719481 PMC: 11668852. DOI: 10.1038/s41541-024-01052-2.


Metabolic reprogramming tips vaccinia virus infection outcomes by stabilizing interferon-γ induced IRF1.

Chang T, Alvarez J, Chappidi S, Crockett S, Sorouri M, Orchard R PLoS Pathog. 2024; 20(10):e1012673.

PMID: 39475961 PMC: 11554218. DOI: 10.1371/journal.ppat.1012673.


Poxviridae Pneumonia.

Nucera F, Bonina L, Cipolla A, Pirina P, Hansbro P, Adcock I Adv Exp Med Biol. 2024; 1451:183-204.

PMID: 38801579 DOI: 10.1007/978-3-031-57165-7_12.


Olfactory immunology: the missing piece in airway and CNS defence.

Wellford S, Moseman E Nat Rev Immunol. 2023; 24(6):381-398.

PMID: 38097777 PMC: 11560121. DOI: 10.1038/s41577-023-00972-9.


Monkeypox Virus in Animals: Current Knowledge of Viral Transmission and Pathogenesis in Wild Animal Reservoirs and Captive Animal Models.

Falendysz E, Lopera J, Rocke T, Osorio J Viruses. 2023; 15(4).

PMID: 37112885 PMC: 10142277. DOI: 10.3390/v15040905.